This week in charts: Brain drugs are back on venture capitalists’ minds
Neuroscience startups raised $1.9B in 2025, with $664M raised by mid-November 2026. Oyster Therapeutics secured $60M for Alzheimer's research. Cell therapy stocks saw mixed reactions to new data, with Cabaletta Bio up 5% and others like Nkarta down over 20%.
